ANALYTICAL QUALITY BY DESIGN APPROACH IN RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF DUVELISIB

SRUJANI CH; ANNAPURNA P; NATARAJ KS; KRISHNA MANJARI PAWAR A

doi:10.22159/ajpcr.2021.v14i2.40181

SRUJANI CH Department of Pharmaceutical Analysis and Quality Assurance, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
ANNAPURNA P Department of Pharmaceutical Analysis and Quality Assurance, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
NATARAJ KS Department of Pharmaceutical Analysis, Shri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India.
KRISHNA MANJARI PAWAR A Department of Pharmaceutical Analysis, Andhra University, Visakhapatnam, Andhra Pradesh, India.

DOI https://doi.org/10.22159/ajpcr.2021.v14i2.40181

Abstract

Objective: A simple, accurate, and robust RP-HPLC method was developed and validated for the estimation of Duvelisib using analytical quality by design approach.

Methods: The critical method parameters (CMP) were systematically optimized using box-Behnken design (BBD). The CMP’s selected were % organic phase composition, column temperature, and flow rate. The critical quality attributes investigated were retention time and theoretical plates.

Results: Chromatographic separation was accomplished on Agilent Zorbax Eclipse C18 (150×4.6 mm, 5 μm) column. The optimized and predicted data from Design Expert software consist of mobile phase 0.1 % orthophosphoric acid (46.3%): Acetonitrile (53.7%), pumped at a flow rate of 0.91 ml/min at 32.6°C gave the highest desirability function of 1. The retention time of the drug was found to be 2.85 min. The developed method was validated as per the ICH Q2 (R1) guidelines.

Conclusion: Based on the analysis of variance values, the selected models were found to be significant with p<0.05. The results of the validation parameters were within the acceptable limit. The stability of the drug was examined under different stress conditions forcibly and significant degradation was found in acidic condition.

Keywords: Analytical quality by design, Box-Behnken design, Duvelisib, Desirability function, Analysis of variance

Author Biography

SRUJANI CH, Department of Pharmaceutical Analysis and Quality Assurance, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.

Departmant of Pharmaceutical Analysis

Assistant Professor

References

1. Rodrigues DA, Sagrillo FS, Fraga CA. Duvelisib: A 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases. Pharmaceuticals (Basel) 2019;12:69.
2. Blair HA. Duvelisib: First global approval. Drugs 2018;78:1847-53.
3. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illes A, Etienne G, et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 2018;132:2446-55.
4. Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, et al. Duvelisib, an oral dual PI3K-?, ? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol 2018;93:1318-26.
5. Shao Y, Xie S, Zhu H, Du X, Xu RA. Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs. J Pharm Biomed Anal 2020;187:113355.
6. Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J, et al. An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 2018;147:590-611.
7. Deepa M, Reddy KR, Satyanarayana SV. A review on quality by design approach for analytical method development. J Pharm Res 2017;11:272-7.
8. Box GEP, Behnken DW. Some new 3 level designs for the study of quantitative variables. Technometrics 1960;2:455-75.
9. ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2 (R1), Current STEP 4 Version. Geneva: International Conference on Harmonisation; 2005.
10. Blessy M, Patel DR, Prajapati NP, Agarwal YK. Development of forced degradation and stability indicating studies of drugs-a review. J Pharm Anal 2014;4:159-65.
11. Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical Experimental Design. 1st ed. New York: Marcel Dekker; 1999.
12. Fukuda IM, Pinto CF, Moreira CS, Saviano AM, Lourenco FR. Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Braz J Pharm Sci 2018;54:e01006.
13. Myers WR. Response surface methodology. In: Chow SC, editor. Encyclopedia of Biopharmaceutical Statistics. 2nd ed. New York: Marcel Dekker; 2003. p. 858-69.
14. Singh S, Singla YP, Arora S. Statistical, diagnostic and response surface analysis of nefopam hydrochloride nanospheres using 35 box-behnken design. Int J Pharm Pharm Sci 2015;7:89-101.
15. Candioti LV, de Zan MM, Camara MS, Goicoechea HC. Experimental design and multiple response optimization. Using the desirability function in analytical methods development. Talanta 2014;124:123-38.
16. Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arab J Chem 2017;10:S3412-25.